Aquestive Therapeutics AQST 深 滬
等待開盤 10-29 09:30:00 美东时间
4.1512
+0.081
+2.00%
華盛通- 最 高4.19
- 今 開4.05
- 成交量 108.99万股
- 最 低 4.01
- 昨 收 4.07
- 總市值 5.21亿
- 52周最高 6.735
- 市盈率 靜 --
- 換手率 0.87%
- 52周最低 2.93
- 委 比 -74.88%
- 總股本 1.26亿
- 歷史最高 20.696
- 量 比 0.81
- 振 幅 4.42%
- 歷史最低 0.618
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aquestive Therapeutics Inc.收跌0.75%，成交额506.32万美元
10月27日，Aquestive Therapeutics Inc.（AQST）收跌0.75%，报3.97美元，成交额506.32万美元，市值4.98亿美元。...
10-27 06:07
Aquestive Therapeutics Inc.收跌6.9%，成交额2031.52万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:11
FDA Accepts Aquestive Therapeutics’ Anaphylm NDA Resubmission; PDUFA Goal Action Date Set For March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 response Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027 Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeut...
10-15 19:15
Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) and Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced an exclusive U.S. licensing and supply agreement Wednesday for LIBERVANT, a treatment for seizure clusters in patients with epilepsy. Under the agreement, Eton will gain exclusive U.S. commercialization...
10-15 01:34
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Eton Pharmaceuticals and Aquestive Therapeutics have entered an exclusive agreement to commercialize LIBERVANT, a buccal film for seizure clusters in epilepsy patients. LIBERVANT, designated as an Orphan Drug, offers a portable alternative to nasal and rectal treatments, with strong patient preference (71%) and a U.S. market potential exceeding $450 million annually. Anticipated launch in April 2027, pending FDA approval, expands Eton's rare dise...
10-14 10:50
Aquestive Therapeutics Adds Veteran Executive to Board
Aquestive Therapeutics ( ($AQST) ) has provided an update. On September 29, 202...
09-29 19:49
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Aquestive Therapeutics appoints Rich Daly, a seasoned life sciences executive with over 30 years of experience, to its Board of Directors. Daly's expertise in commercial launches and biopharmaceutical organizations, including roles at AstraZeneca, Takeda, and Catalyst, will support Aquestive's preparation for the potential launch of Anaphylm. The Board now consists of eight directors, seven of whom are independent. Daly's leadership is expected t...
09-29 11:00
Aquestive Therapeutics Resubmits FDA Application for Pocket-Sized Allergy Treatment
Aquestive Therapeutics Inc. (NASDAQ:AQST) on Thursday said it has officially resubmitted its New Drug Application to the U.S. Food and Drug Administration for Anaphylm. FDA Resubmission The sublingual film aims to treat severe Type I allergic reactions, including life-threatening anaphylaxis. The re...
09-17 23:40
Aquestive resubmits Anaphylm NDA, advancing allergy treatment
An announcement from Aquestive Therapeutics ( ($AQST) ) is now available. On Se...
09-17 19:28
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics has resubmitted its New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film to the FDA, following positive results from human factors and pharmacokinetic studies announced in August 2026. The resubmission aims to address the FDA's Complete Response Letter issued in January 2026, which requested additional studies on packaging, administration, and pharmacokinetics. Anaphylm is designed for rapid treatment...
09-17 11:00
